Sarepta Doubles Market Cap After Long-Awaited Muscular Dystrophy Success

Sarepta Therapeutics is soaring Monday after receiving FDA approval for its Duchenne muscular dystrophy drug candidate eteplirsen, whose gauntlet through divisive committee meetings saw healthcare experts and distraught families.